Remyelination as Neuroprotection

Charles L Howe, Moses Rodriguez

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Remyelination is an important therapeutic goal for the treatment of neurological disease and is likely to protect axons from further injury. Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as multiple sclerosis (MS), spinal cord injury, neurodegeneration, and stroke. The loss of oligodendrocytes and myelin normally associated with demyelinating diseases such as MS is devastating. During the relapsing-remitting phase of MS, the regression of symptoms is likely due to resolution of inflammation and remyelination, resulting in a return of axon function. All of the antibodies that promote remyelination bind to antigens on the surface of oligodendrocytes, suggesting that these antibodies function through direct stimulation of the myelinproducing cells. Treatment with remyelination-promoting growth factor-like human IgM natural autoantibodies may be an efficacious method for quickly repairing demyelinated lesions and maintaining axonal connectivity. Demyelination predisposes axons to subsequent secondary injury. Rapid remyelination of the preserved axons, induced perhaps by treatment with growth factor-like human monoclonal IgM antibodies directed against myelin antigens, may protect them from further injury and thereby preserve neurological function.

Original languageEnglish (US)
Title of host publicationMultiple Sclerosis as A Neuronal Disease
PublisherElsevier Inc.
Pages389-419
Number of pages31
ISBN (Print)9780127387611
DOIs
StatePublished - 2005

Fingerprint

Axons
Oligodendroglia
Demyelinating Diseases
Myelin Sheath
Multiple Sclerosis
Immunoglobulin M
Intercellular Signaling Peptides and Proteins
Wounds and Injuries
Monoclonal Antibodies
Relapsing-Remitting Multiple Sclerosis
Antibodies
Surface Antigens
Spinal Cord Injuries
Autoantibodies
Stroke
Inflammation
Antigens
Neuroprotection
Therapeutics

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Howe, C. L., & Rodriguez, M. (2005). Remyelination as Neuroprotection. In Multiple Sclerosis as A Neuronal Disease (pp. 389-419). Elsevier Inc.. https://doi.org/10.1016/B978-012738761-1/50028-6

Remyelination as Neuroprotection. / Howe, Charles L; Rodriguez, Moses.

Multiple Sclerosis as A Neuronal Disease. Elsevier Inc., 2005. p. 389-419.

Research output: Chapter in Book/Report/Conference proceedingChapter

Howe, CL & Rodriguez, M 2005, Remyelination as Neuroprotection. in Multiple Sclerosis as A Neuronal Disease. Elsevier Inc., pp. 389-419. https://doi.org/10.1016/B978-012738761-1/50028-6
Howe CL, Rodriguez M. Remyelination as Neuroprotection. In Multiple Sclerosis as A Neuronal Disease. Elsevier Inc. 2005. p. 389-419 https://doi.org/10.1016/B978-012738761-1/50028-6
Howe, Charles L ; Rodriguez, Moses. / Remyelination as Neuroprotection. Multiple Sclerosis as A Neuronal Disease. Elsevier Inc., 2005. pp. 389-419
@inbook{ade809a32cde4e618c52610444b0ed5d,
title = "Remyelination as Neuroprotection",
abstract = "Remyelination is an important therapeutic goal for the treatment of neurological disease and is likely to protect axons from further injury. Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as multiple sclerosis (MS), spinal cord injury, neurodegeneration, and stroke. The loss of oligodendrocytes and myelin normally associated with demyelinating diseases such as MS is devastating. During the relapsing-remitting phase of MS, the regression of symptoms is likely due to resolution of inflammation and remyelination, resulting in a return of axon function. All of the antibodies that promote remyelination bind to antigens on the surface of oligodendrocytes, suggesting that these antibodies function through direct stimulation of the myelinproducing cells. Treatment with remyelination-promoting growth factor-like human IgM natural autoantibodies may be an efficacious method for quickly repairing demyelinated lesions and maintaining axonal connectivity. Demyelination predisposes axons to subsequent secondary injury. Rapid remyelination of the preserved axons, induced perhaps by treatment with growth factor-like human monoclonal IgM antibodies directed against myelin antigens, may protect them from further injury and thereby preserve neurological function.",
author = "Howe, {Charles L} and Moses Rodriguez",
year = "2005",
doi = "10.1016/B978-012738761-1/50028-6",
language = "English (US)",
isbn = "9780127387611",
pages = "389--419",
booktitle = "Multiple Sclerosis as A Neuronal Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Remyelination as Neuroprotection

AU - Howe, Charles L

AU - Rodriguez, Moses

PY - 2005

Y1 - 2005

N2 - Remyelination is an important therapeutic goal for the treatment of neurological disease and is likely to protect axons from further injury. Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as multiple sclerosis (MS), spinal cord injury, neurodegeneration, and stroke. The loss of oligodendrocytes and myelin normally associated with demyelinating diseases such as MS is devastating. During the relapsing-remitting phase of MS, the regression of symptoms is likely due to resolution of inflammation and remyelination, resulting in a return of axon function. All of the antibodies that promote remyelination bind to antigens on the surface of oligodendrocytes, suggesting that these antibodies function through direct stimulation of the myelinproducing cells. Treatment with remyelination-promoting growth factor-like human IgM natural autoantibodies may be an efficacious method for quickly repairing demyelinated lesions and maintaining axonal connectivity. Demyelination predisposes axons to subsequent secondary injury. Rapid remyelination of the preserved axons, induced perhaps by treatment with growth factor-like human monoclonal IgM antibodies directed against myelin antigens, may protect them from further injury and thereby preserve neurological function.

AB - Remyelination is an important therapeutic goal for the treatment of neurological disease and is likely to protect axons from further injury. Human monoclonal antibodies that promote remyelination represent a new class of therapeutics for diseases such as multiple sclerosis (MS), spinal cord injury, neurodegeneration, and stroke. The loss of oligodendrocytes and myelin normally associated with demyelinating diseases such as MS is devastating. During the relapsing-remitting phase of MS, the regression of symptoms is likely due to resolution of inflammation and remyelination, resulting in a return of axon function. All of the antibodies that promote remyelination bind to antigens on the surface of oligodendrocytes, suggesting that these antibodies function through direct stimulation of the myelinproducing cells. Treatment with remyelination-promoting growth factor-like human IgM natural autoantibodies may be an efficacious method for quickly repairing demyelinated lesions and maintaining axonal connectivity. Demyelination predisposes axons to subsequent secondary injury. Rapid remyelination of the preserved axons, induced perhaps by treatment with growth factor-like human monoclonal IgM antibodies directed against myelin antigens, may protect them from further injury and thereby preserve neurological function.

UR - http://www.scopus.com/inward/record.url?scp=33747163119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747163119&partnerID=8YFLogxK

U2 - 10.1016/B978-012738761-1/50028-6

DO - 10.1016/B978-012738761-1/50028-6

M3 - Chapter

AN - SCOPUS:33747163119

SN - 9780127387611

SP - 389

EP - 419

BT - Multiple Sclerosis as A Neuronal Disease

PB - Elsevier Inc.

ER -